Sandoz (SWX: SDZ), the Swiss generic drug giant, announced the formation of a dedicated global biosimilars unit designed to sharpen focus on accelerating biosimilars portfolio growth while strengthening core generics operations. The new division will consolidate development, manufacturing, and supply of biosimilar drugs under unified leadership, with Armin Metzger appointed to lead the unit starting April 1, 2026. Metzger joins from Ferring Pharmaceuticals, where he served as Chief Technical Operations Officer, bringing deep biologics manufacturing and operations expertise to Sandoz’s next-generation biosimilars strategy.
Organizational Restructuring
Element
Detail
Company
Sandoz (SWX: SDZ)
New Unit
Global Biosimilars Unit
Scope
Development, manufacturing, and supply consolidation
Biosimilar Interchangeability: Pursue switching studies for automatic substitution designation
Forward‑Looking Statements This brief contains forward‑looking statements regarding organizational effectiveness, portfolio acceleration, and competitive positioning following Sandoz’s biosimilars unit formation. Actual results may differ due to integration challenges, competitive pricing pressures, and regulatory delays in biosimilar approvals.-Fineline Info & Tech
By Fineline Cube 